No results for ‘’
Biofil Chemicals & Pharmaceuticals Ltd
₹32.27
(1.86%)
Sun, 27 Sept 2026, 00:10 am
Health Technology
Pharmaceuticals: Major
24.5KBiofil Chemicals & Pharmaceuticals Price to Sales Ratio (P/S)
| Particulars | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 6.39 | 5.92 | 47.89 | 7.61 | 6 | 7.17 | 16.88 | 12.67 | 51.72 | 22.30 | 9.98 | 86.06 | 134.67 | 120.33 | 138.50 | 120.02 |
| Price to book ratio | 0.68 | 1.22 | 1.99 | 0.88 | 1.03 | 0.56 | 0.40 | 0.50 | 1.21 | 1.79 | 1.85 | 0.79 | 0.81 | 6.62 | 5.59 | 3.90 | 5.40 | 3.56 |
| Price to sales ratio | 1.14 | 1.09 | 1.96 | 2.73 | 1.12 | 0.68 | 0.44 | 0.72 | 1 | 1.69 | 1.97 | 0.47 | 0.41 | 2.99 | 4.20 | 2.25 | 2.45 | 2 |
| Price to cash flow ratio | 2.76 | 0 | 1.24 | 0 | 0 | 0 | 14.80 | 458.87 | 96.46 | 41.37 | 78.01 | 9.82 | 13.06 | 102.45 | 0 | 0 | 41.76 | 0 |
| Enterprise value | 6.53Cr | 6.56Cr | 6.38Cr | 7.08Cr | 9.22Cr | 6.75Cr | 5.81Cr | 7.05Cr | 14.27Cr | 23.8Cr | 25.59Cr | 12.26Cr | 12.98Cr | 107Cr | 94.38Cr | 67.92Cr | 96.38Cr | 67.15Cr |
| Enterprise value to EBITDA ratio | 217.84 | 0 | 7.59 | 0 | 23.48 | 6.67 | 6.01 | 9.60 | 16.39 | 9.08 | 27.34 | 11.98 | 7.12 | 66.81 | 70.82 | 58.17 | 118.05 | 79.24 |
| Debt to equity ratio | 3.79 | 4.29 | 2.45 | 0.19 | 0.36 | 0.38 | 0.37 | 0.36 | 0.13 | 0.11 | 0.12 | 0.12 | 0.08 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 |
| Return on equity % | 0 | -19.66 | 37.24 | 23.53 | 2.23 | 7.69 | 6.83 | 7.26 | 8.14 | 15.27 | 3.65 | 3.60 | 8.46 | 8.01 | 4.24 | 3.28 | 4 | 3.02 |
Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio
The Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Biofil Chemicals & Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Biofil Chemicals & Pharmaceuticals Ltd (NSE: BIOFILCHEM, BSE: 524396) is currently trading at ₹32.27, with a market capitalization of ₹52.56Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio is essential for fundamental analysis.
Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio Current Value
The current Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio stands at 2.
The Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio Historical Trend
The Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 2
- 2023: 2.45
- 2022: 2.25
- 2021: 4.20
- 2020: 2.99
The decline in Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio Indicates for Investors
The Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio Analysis Summary
The Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Biofil Chemicals & Pharmaceuticals Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.